All News

Today we speak with Dr. Robert Coleman about several new agents that have shown promise in early-stage clinical trials for ovarian cancer.

Bone metastases result in poorer outcomes for those patients with advanced renal cell carcinoma (RCC), who were treated with a molecularly targeted therapy. The results were presented in two separate analyses at the annual ASCO meeting.

Researchers found that the more cost-effective option (surgery vs SBRT) in stage I lung cancer depends on whether the disease is clearly or marginally operable.

Here’s a fun fact: most doctors will be sued at least once during their career. Physicians in high-risk specialties such a surgery have a 99% chance of being sued by age 65; even low-risk specialists have a 75% probability.

A group of cancer and other healthcare advocacy organizations applauded a provision in the Affordable Care Act that requires private insurers to cover the routine medical costs of patients participating in clinical trials. However, many of those patients will continue to face roadblocks to participating in trials unless the federal government provides clear guidance on implementation, the groups said in a recent letter.

The first treatment for a rare tumor called giant-cell tumor of the bone has been approved by FDA. The approval of denosumab (Xgeva) was based on a priority FDA review.

Have you ever read someone’s note in the EMR and noticed it says “normal” in every section under physical exam, when in fact, the patient has had a mastectomy, a markedly enlarged liver, 3+ edema, or (horrors!) an amputation that goes undocumented?

The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma.

In our commentary, we will address ways to consider this research across the cancer continuum, with a focus on the cancer survivor, highlighting some of the challenges in interpreting the research evidence for translation into clinical practice and noting some research gaps.

Exercise and physical activity are beneficial along the spectrum of care in cancer patients. However, much more research is needed to better understand this association and guide recommendations for patients.

This article will review these intersections of exercise and oncology, discuss the known mechanisms by which exercise exerts its salutary effects, and touch upon the future directions of exercise research in the oncology setting. Finally, recommendations are provided for clinicians to help patients with and without cancer take advantage of the benefits of physical activity.

Collaboration between oncologists and reproductive endocrinologists/infertility specialists not only will improve patient care, but it also will facilitate advances in the field through cooperative research and education.

How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more.

In the late 1960s, I quickly learned that a large proportion of requests for narcotics in this population were spurious. Patients would simulate renal stone, acute myocardial infarction, and many other painful illnesses in order to obtain narcotic drugs.

The use of magnetic resonance–guided focused ultrasound ablation therapy for the management of painful bone metastases resulted in a high rate of pain response that was rapid, durable, and clinically meaningful, according to an abstract presented at the 2013 ASCO Annual Meeting in Chicago.

The use of a single 8 Gy fraction of re-irradiation for the treatment of painful bone metastases was noninferior to multiple fractions, according to the results of the NCIC CTG SC.20 trial presented at the ASCO 2013 Annual Meeting in Chicago.

Results of a new study indicated that patients with terminal cancer are more likely to have completed a do-not-resuscitate order when they prefer, and believe that their caregiver prefers, comfort at the end of life.

body {background: #000; font-family: Arial, Helvetica, sans-serif; font-size: 12px; color: #FFF; text-align: left; margin-top: 50px;}#wrapper-celgene {border: 1px solid #9c9c9c; width: 965px; padding-bottom: 20px; overflow: hidden; background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/background-celgene.png); background-repeat:repeat-y;}#cn {font-size: 12px; font-weight: bold; margin-bottom: 10px;}#header {margin-left: 25px;}#footer {font-size: 10px; margin-top: 10px;}#wrapper-content {margin: 5px 0 10px 25px;}#panel-left {width: 635px; float: left;}#panel-right {float: left; margin-left: 25px;}#slide {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-off.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide .right{margin: 15px 0 0; float: right; width: 165px;}#slide-hot {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-on.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide-hot .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide-hot .right{margin: 15px 0 0; float: right; width: 165px;}a {color: #fff;}

We speak with two experts to discuss breast cancer risk, genetics, and prevention options available to women at high risk of developing breast and ovarian cancer.

Palliative radiotherapy is an effective means of alleviating pain and improving overall quality of life in elderly patients with bone metastases, according to a new study.

This slide show features images of diffuse osteoblastic bone metastases in a 70-year-old advanced prostate cancer patient, bone metastases in the vertebral column of a kidney cancer patient, and more.

Now is a critical moment for all involved in caring for cancer patients to engage in this national policy debate; numerous cancer advocacy organizations have already joined the effort to oppose the sequester cuts to oncology drugs.